Business
Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the American College of Cardiology 72nd Annual Scientific Session (ACC.23) taking place in New Orleans, LA from March 4, 2023 – March 6, 2023. Title: 1560-153 - Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)Presenter: Ahmad Masri, M.D. M.S., Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science UniversitySession: 1560 - Heart Failure and Cardiomyopathies: Clinical Science 11Date: March 5, 2023Presentation Time: 12:45 PM-1:30 PM Central Time Location: Poster Hall, Hall F Title: 1042-07 - Long-Term Efficacy and Safety of Aficamten in Patients with Symptomatic Obstructive Hypertrophic CardiomyopathyPresenter: Sara Saberi, M.D., Associate Professor, Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan HealthSession: 1042 - Bulking Up: New Research in Hypertrophic CardiomyopathyDate: March 5, 2023Presentation Time: 9:45-9:55 AM Central TimeLocation: Heart Failure and Cardiomyopathies Moderated Poster Theater 11, Hall F Title: 1279-169 - Applicability of the GALACTIC-HF Trial and Omecamtiv Mecarbil to Patients Hospitalized for Heart Failure in the United States: From the GWTG-HF RegistryPresenter: Josephine Harrington, M.D., Fellow, Division of Cardiology, Duke Clinical Research Institute, Duke University School of MedicineSession: 1279 - Heart Failure and Cardiomyopathies: Clinical Science 3Date: March 4, 2023Presentation Time: 11:45-12:30 PM Central TimeLocation: Poster Hall, Hall F About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients wi...